ESPERION THERAPEUTICS INC NE holding history
As of Nov. 6, 2026 (UTC)
| March 31, 2025 | 10,931,257 | $15,741,010 | 0.09% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | May 15, 2025 |
| June 30, 2025 | 10,340,261 | $10,178,953 | 0.05% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Aug. 14, 2025 |
| Sept. 30, 2025 | 7,061,857 | $18,713,921 | 0.10% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Nov. 14, 2025 |
| Dec. 31, 2025 | 9,445,759 | $34,949,308 | 0.21% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Feb. 12, 2026 |
| March 31, 2026 | 15,768,897 | $43,206,778 | 0.29% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | April 21, 2026 |
| June 30, 2026 | 1,930,185 | $6,099,385 | 0.04% | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | July 10, 2026 |
| Sept. 30, 2026 | Absent this quarter | — | — | Withheld — Comparison unavailable: Comparable change withheld pending corporate-action review | Oct. 13, 2026 |
7 rows · Sort by column; scroll horizontally for more.
No rows match these filters.
Schedule 13G disclosures
Esperion Therapeutics, Inc. · SC 13G/A · Event June 30, 2026 · Filed July 14, 2026
| Reporting person | Reported shares | % of security class | Group box |
|---|---|---|---|
| Wasatch Advisors LP | 1,930,185.00 | 0.7% | a |
About reported holdings
13F reports quarter-end securities, excluding cash and shorts. Position changes do not establish trades, motives or returns; portfolio weights use disclosed 13F value.